Log in

NASDAQ:KPTIKaryopharm Therapeutics Stock Price, Forecast & News

$19.25
+0.31 (+1.64 %)
(As of 07/1/2020 04:00 PM ET)
Add
Compare
Today's Range
$18.85
Now: $19.25
$19.72
50-Day Range
$16.60
MA: $18.49
$20.65
52-Week Range
$5.42
Now: $19.25
$29.61
Volume2.23 million shs
Average Volume1.76 million shs
Market Capitalization$1.41 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.51
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIOTM (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency (EMA). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.
Read More
Karyopharm Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.81 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KPTI
CUSIPN/A
Phone617-658-0600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$40.89 million
Book Value$0.79 per share

Profitability

Net Income$-199,590,000.00
Net Margins-316.53%

Miscellaneous

Employees332
Market Cap$1.41 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive KPTI News and Ratings via Email

Sign-up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter.

Karyopharm Therapeutics (NASDAQ:KPTI) Frequently Asked Questions

How has Karyopharm Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Karyopharm Therapeutics' stock was trading at $21.24 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, KPTI shares have decreased by 9.4% and is now trading at $19.25. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Karyopharm Therapeutics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Karyopharm Therapeutics.

When is Karyopharm Therapeutics' next earnings date?

Karyopharm Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Karyopharm Therapeutics.

How were Karyopharm Therapeutics' earnings last quarter?

Karyopharm Therapeutics Inc (NASDAQ:KPTI) issued its earnings results on Tuesday, May, 5th. The company reported ($0.78) EPS for the quarter, missing the Zacks' consensus estimate of ($0.69) by $0.09. The business had revenue of $18.14 million for the quarter, compared to analysts' expectations of $21.59 million. Karyopharm Therapeutics had a negative net margin of 316.53% and a negative return on equity of 208.07%. View Karyopharm Therapeutics' earnings history.

What price target have analysts set for KPTI?

10 equities research analysts have issued 1 year price targets for Karyopharm Therapeutics' shares. Their forecasts range from $25.00 to $41.00. On average, they expect Karyopharm Therapeutics' share price to reach $32.00 in the next twelve months. This suggests a possible upside of 66.2% from the stock's current price. View analysts' price targets for Karyopharm Therapeutics.

Has Karyopharm Therapeutics been receiving favorable news coverage?

Press coverage about KPTI stock has been trending very negative on Thursday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Karyopharm Therapeutics earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about Karyopharm Therapeutics.

Who are some of Karyopharm Therapeutics' key competitors?

What other stocks do shareholders of Karyopharm Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Crispr Therapeutics (CRSP), Bristol-Myers Squibb (BMY), Micron Technology (MU), Alibaba Group (BABA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD) and Amarin (AMRN).

Who are Karyopharm Therapeutics' key executives?

Karyopharm Therapeutics' management team includes the following people:
  • Dr. Michael G. Kauffman, Co-Founder, CEO & Director (Age 56)
  • Dr. Sharon Shacham, Co-Founder, Pres, Chief Scientific Officer & Co-Chairman of Scientific Advisory Board (Age 49)
  • Mr. Christopher Brett Primiano, Exec. VP, Chief Bus. Officer, Gen. Counsel & Sec. (Age 38)
  • Dr. Mansoor Raza Mirza, Clinical Consultant, Member of Scientific Advisory Board & Director (Age 58)
  • Mr. Michael P. Mason, Sr. VP, CFO & Treasurer (Age 44)

What is Karyopharm Therapeutics' stock symbol?

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

How do I buy shares of Karyopharm Therapeutics?

Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Karyopharm Therapeutics' stock price today?

One share of KPTI stock can currently be purchased for approximately $19.25.

How big of a company is Karyopharm Therapeutics?

Karyopharm Therapeutics has a market capitalization of $1.41 billion and generates $40.89 million in revenue each year. The company earns $-199,590,000.00 in net income (profit) each year or ($3.22) on an earnings per share basis. Karyopharm Therapeutics employs 332 workers across the globe.

What is Karyopharm Therapeutics' official website?

The official website for Karyopharm Therapeutics is www.karyopharm.com.

How can I contact Karyopharm Therapeutics?

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company can be reached via phone at 617-658-0600 or via email at [email protected]

This page was last updated on 7/2/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.